China Biologic Products (CBPO) Upgraded by BidaskClub to Sell
BidaskClub upgraded shares of China Biologic Products (NASDAQ:CBPO) from a strong sell rating to a sell rating in a report released on Tuesday morning.
Separately, Zacks Investment Research upgraded shares of China Biologic Products from a sell rating to a hold rating in a research note on Monday, February 5th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and two have issued a buy rating to the company. The stock currently has an average rating of Hold and a consensus target price of $137.50.
Shares of China Biologic Products (NASDAQ:CBPO) opened at $79.73 on Tuesday. China Biologic Products has a 12 month low of $72.21 and a 12 month high of $120.46. The firm has a market cap of $2,648.77, a PE ratio of 17.81, a price-to-earnings-growth ratio of 1.01 and a beta of 1.67.
About China Biologic Products
China Biologic Products Holdings, Inc is a biopharmaceutical company. The Company is principally engaged in the research, development, manufacturing and sales of human plasma-based biopharmaceutical products in China. It operates through the manufacture and sales of human plasma products segment. China Biologic has a product portfolio with over 20 various dosage forms of plasma products and other biopharmaceutical products across nine categories.The Company’s products include human albumin, human immunoglobulin, immunoglobulin for intravenous injection (IVIG), human hepatitis B immunoglobulin, human rabies immunoglobulin, human tetanus immunoglobulin, placenta polypeptide, Factor VIII and human prothrombin complex concentrate (PCC).
Receive News & Ratings for China Biologic Products Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for China Biologic Products and related companies with MarketBeat.com's FREE daily email newsletter.